In the first collaboration of its kind, the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority has brought on GlaxoSmithKline to help the federal agency develop new antibiotics to combat bioterrorism and growing resistance to the drugs.
Sarepta Therapeutics is getting closer to developing a therapy to treat a rare animal-borne disease considered a bioterrorism threat by the Centers for Disease Control and Prevention.
A panel of drug regulators deems a therapy developed by Cangene likely to be effective in humans to protect against a toxin considered a bioterrorism threat.
The Biomedical Advanced Research and Development Authority (BARDA), a unit of the U.S. Department of Health and Human Services (HHS), dismissed a biotech industry proposal for using government bonds rather than contracts to fund projects to advance vaccines and other meds for conditions resulting from bioterrorism, Bloomberg reported.
Uncle Sam has ponied up another $14.5 million in funding to advance Elusys Therapeutics' experimental drug for treating patients after anthrax attacks, according to the company. And the Pine Brook, NJ-based biopharma group is working on a plan for late-stage development of the antibody drug, ETI-204 or Anthim.
After a lingering controversy over bioterror fears that kept a study under wraps for months, investigators have revealed how 5 simple genetic "tweaks" could make the virus spread swiftly among humans.
A panel of U.S. biosecurity officials is asking investigators to keep some of their new research on bird flu under wraps, fearing that terrorists could use the information on the infectious disease
The U.S. government has been given an expensive lesson on just how frustrating new drug research can be. Over the past five years the feds invested a billion dollars in new programs to find and
A new, $50 million biomedical research lab has been completed at George Mason University near Washington D.C. and is being ramped up to study new therapies for infectious diseases--including a range
Seven years and more than $50 billion after 9/11, biosecurity experts say the U.S. still has made only marginal progress developing the security measures and new therapeutics needed to protect the